Paxlovid cost effectiveness
Pro Research Analysisby 
Searched over 200M research papers
Cost-Effectiveness of Paxlovid for COVID-19: Key Insights
Paxlovid Cost-Effectiveness in Elderly and High-Risk Populations
Research consistently shows that Paxlovid is most cost-effective for elderly patients and those at high risk of severe COVID-19. In China, Paxlovid was only cost-effective for people aged over 80, regardless of vaccination status, at the current market price. For younger or vaccinated groups, the price would need to be much lower to be considered cost-effective . Similarly, in African countries like Ghana, Rwanda, and Zambia, Paxlovid was found to be both less costly and more effective than standard care for unvaccinated elderly patients and adults with underlying risk factors. However, it was not cost-effective for the general adult population in these settings . The economic benefit of using Paxlovid increases with patient age and risk level .
Impact of Vaccination Status and Pricing
The cost-effectiveness of Paxlovid is significantly influenced by vaccination status and drug pricing. In vaccinated populations, the benefit of Paxlovid is reduced, making it less likely to be cost-effective unless the price is substantially lowered Zhang2023Edoka2023Pepperrell2022. Scenario analyses indicate that the price threshold for cost-effectiveness is much higher for unvaccinated, older adults compared to younger, vaccinated individuals . The likelihood of early treatment initiation and hospitalization rates are also important factors that affect cost-effectiveness .
Public Health and Economic Benefits
Expanding access to Paxlovid can lead to substantial public health and economic benefits. In the United States, treating 20% of symptomatic COVID-19 cases with Paxlovid could prevent hundreds of thousands of hospitalizations and save billions of dollars, especially in high transmission scenarios . These findings highlight the potential for significant cost savings and improved health outcomes with timely and widespread use of Paxlovid .
Barriers to Global Access and Equity
Despite its potential, access to affordable Paxlovid remains a challenge, especially in low- and middle-income countries (LMICs). Licensing agreements have enabled some LMICs to access generics, but many middle-income countries are excluded and face high prices, limiting cost-effectiveness and delaying pandemic recovery . Additionally, the effectiveness of Paxlovid is reduced in populations with high vaccination rates, and drug interactions with other medications can be a concern .
Prioritization and Resource Allocation
Given limited resources, studies recommend prioritizing Paxlovid for older adults and those at highest risk of severe disease, as the economic cost per death averted decreases with increasing age . Early use in these groups is most beneficial, while widespread use in younger or vaccinated populations is not justified from a cost-effectiveness perspective Zhang2023Edoka2023Zhu2023.
Conclusion
Paxlovid is a cost-effective intervention for preventing severe COVID-19 and reducing mortality, particularly in elderly and high-risk unvaccinated populations. Its cost-effectiveness is highly dependent on patient age, vaccination status, drug price, and timely access. Policymakers should focus on making Paxlovid accessible and affordable for those most likely to benefit, while considering local healthcare infrastructure and resource constraints.
Sources and full results
Most relevant research papers on this topic
Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China
Paxlovid is cost-effective in reducing severe COVID-19 and mortality in people aged over 80 years old, regardless of their vaccination status, at the current marketing price of RMB 1,890.
A cost-effectiveness analysis of Molnupiravir and Paxlovid in three African countries
Paxlovid is more cost-effective than Molnupiravir for elderly COVID-19 patients in Zambia, Rwanda, and Ghana, while both drugs are cost-effective for adults with other risk factors.
DOI
Public Health Impact of Paxlovid as Treatment for COVID-19, United States
Expanding Paxlovid treatment to 20% of symptomatic COVID-19 patients could result in life and cost savings, potentially preventing 0.28 million hospitalizations and saving $56.95 billion in a low-transmission scenario.
Appraisal of evidence reliability and applicability of Paxlovid as treatment for SARS‐COV‐2 infection: A systematic review
Paxlovid significantly reduces death and hospitalization risk in older COVID-19 patients, but does not improve outcomes in patients aged 65 years.
Effectiveness of Paxlovid - a review
Paxlovid effectively reduces the risk of hospitalization or death in COVID-19 patients, but cannot replace vaccination, but its low cost and easy administration make it a valuable tool in combating the disease.
DOI
Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines—A Scoping Review
Paxlovid is an effective oral treatment for COVID-19, with limited data on its use in pregnant and lactating women, but no significant teratogenicity has been observed in these populations.
Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis.
Paxlovid is an effective therapeutic agent for treating COVID-19 patients, reducing hospitalizations, all-cause mortality, and emergency department visits without causing COVID-19 rebound.
Epidemiological study on the effectiveness of Paxlovid.
Paxlovid exposure has a protective effect on COVID-19 outcomes, but adherence to the vaccine is crucial, and potential confounders like comorbidities and immunosuppressants must be considered.
DOI